Vorasidenib and grading of IDH mutant astrocytoma

Neuro-Oncology: The Podcast - A podcast by Neuro-Oncology - Fridays

Description: Dr. Ankush Bhatia interviews Dr. Matthias Preusser about the recent letter in Neuro-Oncology, entitled: "What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?", published in July 2023.